Clinical Trial Update: Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of brivanib alaninate in patients with recurrent or persistent endometrial cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Clear Cell Adenocarcinoma
• Endometrial Mixed Adenocarcinoma
• Endometrial Mucinous Adenocarcinoma
• Endometrial Serous Adenocarcinoma
• Endometrial Squamous Cell Carcinoma
• Endometrial Transitional Cell Carcinoma
• Endometrial Undifferentiated Carcinoma

Drugs mentioned

• Brivanib alaninate (brivanib alaninate)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-11-06